Loading
A phase 3 trial of Dato-DXd in HR-positive / HER2-negative breast cancer, run by AstraZeneca, now recruiting.
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer is a phase 3 interventional study registered as NCT07205822 by AstraZeneca, with 100 participants planned, started 2025-10-30 and due to reach its primary completion in 2028-02-02. Interventions recorded: Dato-DXd.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/